Revilico Inc.

Exciting Developments Ahead for Revilico Inc! After countless hours of hard work, our team at Revilico is gearing up to launch new AI-driven solutions for drug discovery, with plans to expand into wet lab research to pursue drug targets and advance our small molecule cancer therapeutic pipeline. Join us at the 8th SoCal Taiwanese Biotechnology Association (TBA) Annual Symposium, an event focused on AI’s impact on healthcare and pharmaceutical development, at UCLA's Covel Commons on November 2nd. Our CEO, Christopher Korban, will be giving a dedicated talk about Revilico Inc.—sharing insights into our current and future approaches in small molecule drug discovery and our vision for integrating AI with wet lab research to drive progress. Stay tuned for more updates—and don’t forget to RSVP through the link in the comments!?(edited)?

We’re excited to share that Revilico Inc. will be presenting at the Clinical Tools Symposium, hosted at Aquillius in San Diego today! We invite everyone to join us and learn more about how we’re driving innovation in drug discovery. Don’t miss the opportunity to engage with us at this exciting event!

October is Breast Cancer Awareness Month Revilico Inc. is actively focusing on accelerating the discovery of new therapeutics for breast cancer, with an emphasis on triple-negative breast cancer—an aggressive and hard-to-treat subtype. Our latest article provides a comprehensive overview of the current state of breast cancer treatments, as well as future directions and innovations in therapeutic development. We aim to contribute to advancing the understanding and treatment of this disease through?AI-driven drug discovery to bring greater hope to patients battling this disease. We invite you to read and engage with our work as we continue to push boundaries of drug discovery!

We are happy to share that Revilico Inc. has been accepted into the NVIDIA Inception Program! This partnership will help us enhance our AI-driven drug discovery efforts, leveraging NVIDIA’s computational infrastructure and commercial network to accelerate the development of affordable pharmaceuticals and bring them to market more quickly. We’re excited about this new chapter and invite you to follow our journey as we continue to innovate the field of drug discovery! #Revilico #NVIDIA #NVIDIAInception #DrugDiscovery #AI #Pharmaceuticals

Welcome to the final week of our 10-Week Series! It’s been an incredible 10 weeks diving into the intersection of AI and drug repurposing, from discovery to clinical trial submissions and everything in between. In this week’s article, we're excited to share more about Revilico’s business model and how we’re tackling the scientific challenges we've discussed in previous weeks. To learn more about our software platform and how we screen millions of compounds to treat diseases like cancer with Artificial Intelligence, subscribe to our newsletter and get in touch with our founding team—we’d love to connect!

Welcome to Week 9 of Our 10-Week Series! Over the past weeks, we've covered the drug development process and finally finished up with Stage 5, Post-Market Surveillance. After covering the entire process from start to finish, this week we are focusing on the challenges of AI implementation into the drug development pipeline. Key Highlights: Challenges in AI: AI faces challenges like bias, transparency, and generalization, which stem from imperfect data and algorithms. While companies aim to address these issues through improved data practices and transparency, integration of AI/ML into processes remains costly and complex, with risks of errors and ethical concerns. Human oversight continues to be crucial as AI/ML technologies evolve, balancing efficiency with the need for careful management. Case Studies of AI in Biotech: AI/ML implementation in drug discovery faces challenges such as biased data and overoptimistic predictions, leading to issues like underperformance in clinical predictions and financial losses from flawed models. However, successful cases like Exscientia's AI-designed drug candidate for OCD highlight AI/ML's potential to significantly enhance efficiency and reduce research time and costs. ?? Explore the Full Article Read our article about the challenges AI/ML algorithms face while operating in the drug development pipeline. ?? Discover More and Stay Informed Read the complete article and subscribe to our newsletter to keep up with the latest trends and updates in drug discovery and regulatory developments. #DrugDevelopment #ClinicalTrials #AI #Biotech #Healthcare #AIChallenges #RevilicoInc

Welcome to Week 8 of Our 10-Week Series! Over the past few week's we've covered the drug development pipeline focusing on the regulatory considerations in drug development. This week, we shift our focus to the final stage of drug development, Post-Market Surveillance for Approved Drugs. Key Highlights: After the entire drug development process, unexpected outcomes can still occur. Therefore the FDA conducts Post-Market Surveillance to monitory approved drugs for adverse reactions that were not detected through clinical trials. The FDA uses the Sentinel Initiative, which includes the Sentinel System and FDA-Catalyst, to analyze electronic healthcare data and identify potential risks. This program may possibly lead to a future with automated post-market surveillance through AI and ML. ??Dive into our detailed article about Post-Market Surveillance. ? Discover More and Stay Informed ??Read the complete article and subscribe to our newsletter to keep up with the latest trends. #DrugDevelopment #ClinicalTrials #AI #Biotech #Healthcare #RegulatoryAffairs #RevilicoInc

Welcome to Week 7 of Our 10-Week Series! Over the past few weeks, we've explored the key stages of clinical trials, focusing on Phase I-III, where human testing evaluates drug efficacy, safety, and tolerability. Last week, we highlighted the critical role of Phase III in generating comprehensive data before market approval. This week, we shift our focus to the regulatory considerations essential for navigating the drug development process and ensuring that new therapies safely reach the market. Key Highlights: Regulatory Considerations in Drug Development: Navigating the regulatory landscape is as challenging as the science itself. From ensuring compliance during preclinical research to securing FDA approval through INDs, NDAs, and BLAs, every step is crucial to guarantee the quality, safety, and efficacy of new drugs. Global Harmonization and Compliance: While our discussion focuses on the FDA, it's important to note the role of global regulatory bodies like the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency. Harmonization efforts, such as ICH and MRAs, ensure a more unified approach to drug regulation worldwide. Regulatory Pathways for Drug Repurposing: Drug repurposing offers a faster and more cost-effective path to market, but it comes with its own set of regulatory challenges. Patent considerations, existing data utilization, and label updates are key aspects that must be addressed to ensure compliance. AI in Drug Development, The Regulatory Frontier: The integration of AI and machine learning into drug development is gaining momentum, with the FDA recognizing the potential of these technologies. As we anticipate further regulatory guidance in this area, the industry is poised for innovation that could revolutionize drug discovery and delivery. ?? Explore the Full Article Dive into our detailed discussion on the regulatory hurdles and innovations shaping the future of drug development. Stay ahead with insights on how these evolving guidelines impact the journey from lab to market. ?? Discover More and Stay Informed Read the complete article and subscribe to our newsletter to keep up with the latest trends and updates in drug discovery and regulatory developments. #DrugDevelopment #ClinicalTrials #AI #Biotech #Healthcare #RegulatoryAffairs #NexabioVentureSolutions

Proud to announce that we're showcasing at Step San Francisco 2024! Swing by our booth to meet the Revilico team and learn about our AI-driven drug discovery innovations. We're excited to share our journey and network with investors and fellow entrepreneurs. Let's connect and explore new opportunities together! #StepSF2024 https://lnkd.in/gbqk_GCt

We are thrilled to announce that Nexabio Venture Solutions is officially rebranding to Revilico Inc! This new identity marks a significant milestone in our journey, reflecting our growth, innovation, and the bold vision we have for the future of drug discovery and AI-powered therapeutics. Our rebrand to Revilico Inc. aligns with our commitment to revolutionizing the landscape of drug discovery. The name "Revilico" symbolizes our relentless drive to rethink, redefine, and revitalize the drug development process through cutting-edge technology, including advanced in silico modeling, AI-driven drug design, and innovative solutions that push the boundaries of what’s possible in therapeutic development. What’s New? We are expanding our focus to bring more transformative AI solutions to drug repurposing and development. Our mission remains clear— to accelerate drug discovery with precision, efficiency, and impact, ultimately bringing life-saving treatments to market faster. As Revilico Inc., we’re introducing new tools and platforms that will empower researchers, biotech firms, and pharmaceutical companies to unlock new possibilities in therapeutic development. What Stays the Same? Our dedication to delivering exceptional value and breakthrough results for our partners and clients remains unwavering. We continue to work closely with you to advance our shared goals and create meaningful impact in the healthcare industry. Join Us on This Journey! As we embark on this exciting new chapter, we want to thank our developers, engineers, advisors, partners, and supporters who have been part of our story so far. We are excited to have you with us as we take Revilico Inc. to new heights. Stay tuned for more updates, and feel free to reach out to our team if you have any questions about our rebrand or what’s ahead. Let’s revolutionize the future of drug discovery together! #RevilicoInc #Rebranding #AI #DrugDiscovery #Innovation #Pharma #Biotech